Literature DB >> 20206137

Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities.

Barbara Bosier1, Giulio G Muccioli, Emmanuel Hermans, Didier M Lambert.   

Abstract

The CB(1) and CB(2) cannabinoid receptors are G protein-coupled receptors (GPCRs) recognized by a variety of endogenous ligands and activating multiple signalling pathways. This multiplicity of ligands and intracellular transduction mechanisms supports a complex control of physiological functions by the endocannabinoid system, but requires a finely tuned regulation of the signalling events triggered on receptor activation. Here we review the diverse signalling pathways activated by the cannabinoid receptors and discuss the mechanisms allowing for specificity in the associated functional responses triggered by endogenous or exogenous ligands. At variance with the classical concept that all agonists at a given GPCR induce a similar repertoire of downstream events in all tissues, we also summarize the experimental evidence supporting the existence of functional selectivity and protean agonism at cannabinoid receptors. By placing emphasis on the ligand- or constitutive activity-dependent specifications of receptor-G protein coupling, these concepts explain how distinct cannabinoid ligands may activate specific downstream mediators. Finally, although both the diversity and specificity in cannabinoid signalling are now established in vitro, few data are available from in vivo studies. Therefore, we conclude this review by examining the experimental evidence supporting the physiological relevance of this complexity in the cannabinoid system. The ability to selectively manipulate physiological functions, through activation of defined signalling cascades, will in all likelihood help in the development of efficacious and safe cannabinoid-based therapeutics for a variety of indications. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20206137     DOI: 10.1016/j.bcp.2010.02.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  63 in total

1.  Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

Authors:  Torbjörn U C Järbe; Hongfen Deng; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions.

Authors:  Vikas Saini; Daniel M Staren; Joshua J Ziarek; Zayd N Nashaat; Edward M Campbell; Brian F Volkman; Adriano Marchese; Matthias Majetschak
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

4.  Differentiation between low- and high-efficacy CB1 receptor agonists using a drug discrimination protocol for rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Aneetha Halikhedkar; JodiAnne Wood; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

Review 5.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

6.  Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Authors:  Lirit N Franks; Benjamin M Ford; Nikhil R Madadi; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Eur J Pharmacol       Date:  2014-05-20       Impact factor: 4.432

7.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

Review 8.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

9.  Structural equation modeling of food craving across the menstrual cycle using behavioral, neuroendocrine, and metabolic factors.

Authors:  Sridevi Krishnan; Karan Agrawal; Rebecca R Tryon; Lucas C Welch; William F Horn; John W Newman; Nancy L Keim
Journal:  Physiol Behav       Date:  2018-07-18

10.  The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects.

Authors:  Lirit N Franks; Benjamin M Ford; Toshifumi Fujiwara; Haibo Zhao; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2018-06-12       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.